Q1 Earnings Estimate for Immatics Issued By Leerink Partnrs

Immatics (NASDAQ:IMTX) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Immatics in a note issued to investors on Thursday, March 27th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings per share of ($0.39) for the quarter. The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share. Leerink Partnrs also issued estimates for Immatics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS and Q4 2025 earnings at ($0.41) EPS.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.51. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The business had revenue of $15.67 million during the quarter, compared to analyst estimates of $16.16 million.

Immatics Stock Down 1.7 %

NASDAQ:IMTX opened at $4.63 on Monday. Immatics has a 52 week low of $4.06 and a 52 week high of $13.77. The company has a market cap of $552.62 million, a PE ratio of -7.02 and a beta of 0.83. The business’s 50 day moving average is $4.96 and its two-hundred day moving average is $7.43.

Hedge Funds Weigh In On Immatics

A number of hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its stake in Immatics by 7.6% in the fourth quarter. Wellington Management Group LLP now owns 10,417,892 shares of the company’s stock valued at $74,071,000 after acquiring an additional 736,709 shares during the period. Frazier Life Sciences Management L.P. boosted its position in shares of Immatics by 58.6% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 2,147,911 shares of the company’s stock worth $15,272,000 after buying an additional 793,200 shares during the period. Zimmer Partners LP grew its stake in shares of Immatics by 44.6% in the fourth quarter. Zimmer Partners LP now owns 405,000 shares of the company’s stock worth $2,880,000 after purchasing an additional 125,000 shares in the last quarter. Vestal Point Capital LP grew its stake in shares of Immatics by 67.3% in the fourth quarter. Vestal Point Capital LP now owns 6,275,000 shares of the company’s stock worth $44,615,000 after purchasing an additional 2,525,000 shares in the last quarter. Finally, Suvretta Capital Management LLC acquired a new position in shares of Immatics during the fourth quarter valued at $36,014,000. Institutional investors and hedge funds own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.